Dupixent rival lands in Aust

Tough competition appears to be on the horizon for Sanofi's Dupixent with the TGA accepting Galderma's nemolizumab for review under the Access Consortium Framework for two indications.

To see the whole article please log in.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here